Brought to you by 
Series D round brings in €3.9mm for Novaliq
24 Mar 2017
Executive Summary
Drug delivery firm Novaliq GMBH has raised €3.9mm ($5.2mm) through its Series D venture round. Dievini Hopp Bio Tech Holding GMBH & Co. KG was the sole investor.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D round brings in €3.9mm for Novaliq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice